AVITA Medical Inc (AVHHL) (Q3 2026) Earnings Call Highlights: Revenue Surges 53%

AVITA Medical Inc reported Q3 2026 revenue of $26.1M, up 53% YoY, with U.S. Resell revenue rising 20% sequentially. Gross margin expanded to 84%, and operating expenses remained flat. Full-year revenue guidance was raised to $92M-$94M. Q3 growth may have included $1M from seasonal factors, and Q4 guidance suggests potential deceleration. The company expects cash flow breakeven in Q4 and flat operating expenses in 2027, with growth driven by new reimbursement frameworks and product adoption.

Original reporting
Published Nov 6, 2026, 5:25 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 5:39 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AVITA Medical Inc (AVHHL) (Q3 2026) Earnings Call Highlights: Revenue Surges 53% — source image
Decision brief

The 30-second read

$AVHHLBullishMed
01

Why it matters

Earnings beat and guidance raise are likely to attract short‑term buying interest.

02

Market read

First report of earnings with strong numbers; micro‑cap but material for traders focused on healthcare small caps.

03

What to watch

Potential margin pressure from lower‑margin product mix and flat international revenue.

Relevance 7/10Novelty 7/10Timing: today after earnings release

Background

AVITA Medical Inc (AVHHL) reported its Q3 2026 earnings, highlighting revenue surge, margin expansion, and upgraded guidance.

Company-level read

Ticker impact

$AVHHLBullishHigh confidence
Context

Q3 2026 earnings call disclosed 53% YoY revenue growth to $26.1M, 84% gross margin, and raised full-year guidance to $92-$94M.

Expected impact

likely upside as market prices in revenue beat and raised guidance

Evidence & confidence

Revenue and margin beat, cash use down, and guidance raised indicate improved fundamentals.

Market effects

Positive signal for medical device and wound-care sector as growth accelerates.

U.S. market may see modest buying pressure in small-cap healthcare stocks.

Limited to niche medical‑technology segment.

Counterpoint

Seasonal boost may not repeat; guidance still modest, so upside could be limited.

Key entities

  • AVITA Medical Inc

    Medical device maker reporting Q3 2026 results.

  • Kerry Vance

    CEO providing commentary on growth drivers.

Related articles

$PANWHighAI 9/10

Palo Alto Networks Reports Fiscal First Quarter 2027 Financial Results

Palo Alto Networks Inc (PANW) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Palo Alto Networks Reports Fiscal First Quarter 2027 Financial Results SANTA CLARA, Calif., Nov. 18, 2026 — Palo Alto Networks ® (NASDAQ: PANW), the global AI cybersecurity leader, announced today financial results for its fiscal first quarter ended October 31, 2026.

$IPARMedAI 8/10

INTERPARFUMS, INC. ANNOUNCES FULL YEAR 2027 GUIDANCE

INTERPARFUMS INC (IPAR) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 FOR IMMEDIATE RELEASE INTERPARFUMS, INC. ANNOUNCES FULL YEAR 2027 GUIDANCE New York, New York, November 18, 2026, Interparfums, Inc. (NASDAQ GS: IPAR) (“Interparfums” or the “Company”) today announced initial guidance for its fiscal year ending December 31, 2027. In

$SNEXMedAI 8/10

StoneX Reports Record Fiscal 2026 Results; Net Income Rises 72% to $525.4 Million

StoneX reported record fiscal 2026 results with net income of $525.4 million, up 72% year over year, and net operating revenues of $2.93 billion, up 43%. Fourth-quarter net income was $84.2 million, and net operating revenues were $655.2 million. Diluted EPS was $4.15 for the year and $0.66 for the quarter. The R.J. O’Brien acquisition contributed $195.8 million in operating revenue during the quarter.

$WWDMedAI 8/10

Woodward falls on soft guidance despite fourth quarter beat

Woodward Inc (WWD) reported Q4 2026 adjusted EPS of $2.83, beating estimates by $0.30, and revenue of $1.2B, up 17% YoY. However, its fiscal 2027 guidance fell short of expectations, with EPS projected at $10.20-$10.70, below the $10.76 consensus. Shares dropped 1.7% in after-hours trading. The company reported full-year 2026 adjusted EPS of $9.78, up 42% YoY, and net sales of $4.4B, up 22% YoY.

$KRNTMedAI 8/10

Kornit (KRNT) Q3 2026 Earnings Call Transcript

Kornit (KRNT) reported Q3 2026 revenue of $58.3M, up 9.8% YoY. The company highlighted growth in recurring revenue, with 80% of revenue being recurring or highly recurring. Annual recurring revenue (ARR) reached $39.4M, up 83% YoY. Kornit expects Q4 revenue between $60M and $65M, with adjusted EBITDA margin between 6.5% and 9%. The company is seeing strong adoption of its all-inclusive click (AIC) model and is expanding its customer base, including traditional screen printers.

$SNEXMedAI 8/10

StoneX Group falls after fourth quarter earnings miss

StoneX Group Inc. (SNEX) reported Q4 earnings of $0.66 per share, missing estimates of $0.81. Revenue rose 12% YoY to $655.2M, but net income fell 2% to $84.2M. Full-year 2026 results showed record net income of $525.4M, up 72% YoY, and revenue of $2.9B, up 43% YoY. The stock dropped 6.2% in after-hours trading.